Bacterial vaginosis - Pipeline Insight, 2024

Bacterial vaginosis - Pipeline Insight, 2024

DelveInsight’s, “Bacterial vaginosis - Pipeline Insight, 2024,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Bacterial vaginosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Bacterial vaginosis Understanding

Bacterial vaginosis: Overview

Bacterial vaginosis is the most common cause of abnormal vaginal discharge or malodor, affecting up to one third of US women. Most women with bacterial vaginosis are unaware of the infection, making it difficult to diagnose in the absence of a microscopic examination of vaginal discharge or using point-of-care testing. Untreated bacterial vaginosis elevates the risk of postoperative surgical infections in women undergoing obstetric and gynecological procedures. Treatment with antimicrobial agents that target bacterial vaginosis has been shown to reduce the rate of postoperative infections following hysterectomy and surgical abortions.

""Bacterial vaginosis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bacterial vaginosis pipeline landscape is provided which includes the disease overview and Bacterial vaginosis treatment guidelines. The assessment part of the report embraces, in depth Bacterial vaginosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bacterial vaginosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Bacterial vaginosis R&D. The therapies under development are focused on novel approaches to treat/improve Bacterial vaginosis.

Bacterial vaginosis Emerging Drugs Chapters

This segment of the Bacterial vaginosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bacterial vaginosis Emerging Drugs

• LACTIN-V: Osel Inc

Osel’s LACTIN-V is a live biotherapeutic product addressing women’s health disorders. LACTIN-V is under IND for preventing BV and rUTI. It contains Lactobacillus crispatus CTV-05, a single strain of hydrogen peroxide-producing vaginal Lactobacillus that is part of the natural vaginal microbiome of many healthy women. LACTIN-V targets clinical indications associated with dysbiosis of the vaginal microbiota where hydrogen peroxide-producing lactobacilli are depleted, such as bacterial vaginosis (BV) and recurrent urinary tract infections (rUTI). LACTIN-V is delivered vaginally with a proprietary applicator. The drug is currently in phase II stage of clinical trial evaluation to treat Bacterial vaginosis.

• Radezolid: Melinta Therapeutics

Radezolid is a second-generation oxazolidinone antibiotic that is being developed by Melinta Therapeutics. The drug is currently in preclinical phase of development to treat bacterial vaginosis.

Further product details are provided in the report……..

Bacterial vaginosis: Therapeutic Assessment

This segment of the report provides insights about the different Bacterial vaginosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Bacterial vaginosis

There are approx. 6+ key companies which are developing the therapies for Bacterial vaginosis. The companies which have their Bacterial vaginosis drug candidates in the most advanced stage, i.e. phase II include, Osel Inc.

• Phases

DelveInsight’s report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Bacterial vaginosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bacterial vaginosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bacterial vaginosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bacterial vaginosis drugs.

Bacterial vaginosis Report Insights

• Bacterial vaginosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Bacterial vaginosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Bacterial vaginosis drugs?
• How many Bacterial vaginosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bacterial vaginosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bacterial vaginosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Bacterial vaginosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Osel Inc
• Evofem Biosciences
• LUCA Biologics
• Melinta Therapeutics
• TenNor Therapeutics
• Mayfield Pharmaceuticals
• Toltec Pharmaceuticals

Key Products

• LACTIN-V
• Radezolid
• TNP 2198
• MAY-66
• TOL 463